SAN FRANCISCO & WALTHAM, Mass.--(BUSINESS WIRE)--Avila Therapeutics, a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, today presented, for the first time, results of studies on its orally available, novel Bruton’s Tyrosine Kinase (Btk) inhibitor, AVL-101. These data show that AVL-101 potently and selectively targets B cell malignancies, thereby disrupting their survival, through the covalent and sustained inhibition of Btk. Further, AVL-101 showed the potential to completely silence the disease-associated protein by demonstrating prolonged duration of action in the inhibition of Btk, a protein that has been shown to have a central role in the function of B cells and their malignant counterparts. These findings support the potential of AVL-101 in B-cell related hematological cancers, such as non-Hodgkin’s lymphoma (NHL) and B cell chronic lymphocytic leukemia (B-CLL). These data were presented today at the 50th American Society of Hematology annual meeting.
